Abemaciclib vs Palbociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02107703 · Phase 3 · active, not recruiting
This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.
Next expected readout: December 2026 · NCT05305924 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)
Result source: NCT02107703
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)
Result source: NCT02297438
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Abemaciclib | Palbociclib |
|---|---|---|
| PFS, median | 16.4 vs 9.3+7.1 vs placeboNCT0210770311 other results
| 24.8 vs 14.5+10.3 vs placeboNCT0174042720 other results
|
| OS, median | 45.8 vs 37.3+8.5 vs placeboNCT021077036 other results
| 53.9 vs 51.2+2.7 vs placeboNCT0174042714 other results
|
| ORR | 35.2% vs 16.1%+19.1 vs placeboNCT021077034 other results
| 46.4% vs 38.3%+8.1 vs placeboNCT0174042715 other results
|
| Clinical benefit rate | 72.2% vs 56.1%+16.1 vs placeboNCT021077038 other results
| 85.8% vs 71.2%+14.6 vs placeboNCT0174042710 other results
|
PFS, median
- Abemaciclib
- 16.4 vs 9.3+7.1 vs placeboNCT02107703
11 other results
- 8.3 vs 5.7 NCT02675231
- 5.7 vs 5.7 NCT02675231
- 6.3 vs 1.9 NCT03280563
- 6 NCT02102490
- 2.1 NCT03099174
- 13.6 NCT03099174
- 33.1 NCT03099174
- 2.1 NCT02308020
- 4.4 NCT02308020
- 1.4 NCT02308020
- 1.2 NCT02308020
- Palbociclib
- 24.8 vs 14.5+10.3 vs placeboNCT01740427
20 other results
- 21.5 vs 13.9 NCT02297438
- 9.2 vs 3.8 NCT01942135
- 7.3 vs 10 NCT02028507
- 7.5 vs 10 NCT02028507
- 21.6 vs 16.4 NCT02297438
- 8 vs 10.6 NCT02028507
- 20.2 vs 10.2 NCT00721409
- 26.1 vs 10.2 NCT00721409
- 18.1 vs 10.2 NCT00721409
- 11.3 NCT02630693
- 9.3 NCT02630693
- 9.1 NCT02668666
- 16.9 NCT03530696
- 8.3 NCT03530696
- 4.1 NCT02913430
- 9.4 NCT02384239
- 6.5 NCT02384239
- 29.4 NCT03633331
- 30.4 NCT03691493
- 18.6 NCT02499146
OS, median
- Abemaciclib
- 45.8 vs 37.3+8.5 vs placeboNCT02107703
6 other results
- 26.7 vs 26.0 NCT03280563
- 22.3 NCT02102490
- 10.1 NCT02308020
- 13.4 NCT02308020
- 7.1 NCT02308020
- 2.9 NCT02308020
- Palbociclib
- 53.9 vs 51.2+2.7 vs placeboNCT01740427
14 other results
- 53.8 vs 49.8 NCT01740427
- 51.7 vs 51.5 NCT02297438
- 50.3 vs 49.7 NCT02297438
- 34.9 vs 28 NCT01942135
- 33.7 vs 32 NCT02028507
- 37.5 vs 34.5 NCT00721409
- 37.5 vs 34.5 NCT00721409
- 35.1 vs 34.5 NCT00721409
- 21.4 NCT02630693
- 20.7 NCT02630693
- 35.6 NCT03633331
- 35.1 NCT03530696
- 37.9 NCT03691493
- 18.8 NCT02913430
ORR
- Abemaciclib
- 35.2% vs 16.1%+19.1 vs placeboNCT02107703
4 other results
- 26.3% vs 10% NCT03280563
- 19.7% NCT02102490
- 32.9% vs 13.9% NCT02675231
- 13.9% vs 13.9% NCT02675231
- Palbociclib
- 46.4% vs 38.3%+8.1 vs placeboNCT01740427
15 other results
- 37.3% vs 31.6% NCT02297438
- 43.4% vs 38% NCT02297438
- 40.2% vs 33.9% NCT02297438
- 52.3% vs 43.5% NCT02297438
- 21% vs 8.6% NCT01942135
- 42.9% vs 33.3% NCT00721409
- 44.1% vs 33.3% NCT00721409
- 42% vs 33.3% NCT00721409
- 55.4% vs 39.4% NCT00721409
- 55.6% vs 39.4% NCT00721409
- 55.3% vs 39.4% NCT00721409
- 47.6% NCT01684215
- 30% NCT02668666
- 33.3% NCT00721409
- 19.2% NCT02499146
Clinical benefit rate
- Abemaciclib
- 72.2% vs 56.1%+16.1 vs placeboNCT02107703
8 other results
- 58.2% vs 38% NCT02675231
- 45.6% vs 38% NCT02675231
- 42.1% vs 15% NCT03280563
- 42.4% NCT02102490
- 13% NCT02308020
- 26.9% NCT02308020
- 26.1% NCT02308020
- 9.1% NCT02308020
- Palbociclib
- 85.8% vs 71.2%+14.6 vs placeboNCT01740427
10 other results
- 79.3% vs 80.1% NCT02297438
- 77.9% vs 79.6% NCT02297438
- 76.9% vs 73.1% NCT02297438
- 78.1% vs 71.8% NCT02297438
- 66.3% vs 39.7% NCT01942135
- 81% vs 58% NCT00721409
- 76.5% vs 58% NCT00721409
- 84% vs 58% NCT00721409
- 64% NCT02668666
- 83.3% NCT00721409
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. Abemaciclib: 12 of 12 rows · Palbociclib: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Abemaciclib Rows use multiple source trials | Palbociclib Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 42.4% (n=132)a,b,c NCT02102490 · Phase 2 4 other source trials13% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.9% (n=52) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.1% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence 9.1% (n=22) NCT02308020 · Phase 2 · registry result, not featured evidence | 64% (n=47)a,b,c NCT02668666 · Phase 2 · registry result, not featured evidence 1 other source trial83.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| Disease Control responder rate · % of participants No placebo or comparator arm | 67.4% (n=132)d,b,c NCT02102490 · Phase 2 4 other source trials40.7% (n=27) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 51.7% (n=58) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 39.3% (n=28) NCT02308020 · Phase 2 · registry result, not featured evidence 26.1% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence | 85.7% (n=42)125 mg + 2.5 mgd,b,c NCT01684215 · Phase 2 · registry result, not featured evidence · combination 1 other source trial65.4% (n=26) NCT02499146 · Phase 1 · registry result, not featured evidence · combination |
| Duration of Response time to event · months | NA vs 25.6 placebo monthse,c NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 13.36 vs 13.03 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 20.1 vs 16.7 placebo monthse,c NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7 other source trials10.4 vs 9 Fulvestrant months NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 22.4 vs 19.4 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 30.3 vs 24.9 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.7 vs 11.2 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 20.9 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.2 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.3 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 8.6 monthsa,b,c NCT02102490 · Phase 2 4 other source trials11.12 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 17.54 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 5.78 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 4.63 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 5.55 months*125mgf,a,b,c NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted show 1 more dose4.14 months*100mg NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 19.7% (n=132)a,b,c NCT02102490 · Phase 2 | 30% (n=47)a,b,c NCT02668666 · Phase 2 · registry result, not featured evidence 3 other source trials47.6% (n=42)125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 19.2% (n=26) NCT02499146 · Phase 1 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 60.6% (n=33)*1000 mgf,g,d,c NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted show 3 more doses19.4% (n=31)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 3.8% (n=26)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 6.7% (n=15)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted | 33.3% (n=54)*g,d,c NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted 8 other source trials0% (n=3) @ 24wk*100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 6.7% (n=15) @ 24wk*150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 10% (n=10) @ 24wk*300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 0% (n=16) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=6) @ 24wk*75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 4% (n=75) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted |
| Overall Survival time to event · months No placebo or comparator arm | 22.32 monthsa,b,c NCT02102490 · Phase 2 4 other source trials10.06 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 13.38 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 7.13 months NCT02308020 · Phase 2 · registry result, not featured evidence 2.93 months NCT02308020 · Phase 2 · registry result, not featured evidence | 35.61 months*a,b,c NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted 8 other source trials20.73 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 21.39 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence NA months NCT03530696 · Phase 2 · registry result, not featured evidence 35.1 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 37.9 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination NA months125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination NA months NCT02913430 · Phase 1 · registry result, not featured evidence · combination 18.7541 months NCT02913430 · Phase 1 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 6 monthsa,b,c NCT02102490 · Phase 2 8 other source trials2.07 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 4.41 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 1.45 months NCT02308020 · Phase 2 · registry result, not featured evidence 1.22 months NCT02308020 · Phase 2 · registry result, not featured evidence 13.6 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 2.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination NA months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 29.4 months*a,b,c NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted 11 other source trials9.33 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 11.3 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence 9.13 months NCT02668666 · Phase 2 · registry result, not featured evidence 8.3 months NCT03530696 · Phase 2 · registry result, not featured evidence 16.9 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 30.4 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination 6.53 months100mg NCT02384239 · Phase 2 · registry result, not featured evidence 9.4 months125mg NCT02384239 · Phase 2 · registry result, not featured evidence 18.6 months NCT02499146 · Phase 1 · registry result, not featured evidence · combination 4.131147 months NCT02913430 · Phase 1 · registry result, not featured evidence · combination NA months NCT02913430 · Phase 1 · registry result, not featured evidence · combination |
| Dropout rate | 25.6%h NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results5.3% NCT02102490 · Phase 2 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 16.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 8.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 25%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 34.5%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 17.5% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestonei NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more resultsn/a: no completion milestone NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestone NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 69.1%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 34%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02600923 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 1.1%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 0%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 1.4% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence 12.5%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 2.6%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination 2.8% NCT03691493 · Phase 2 · registry result, not featured evidence · combination 0%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%100mg NCT02384239 · Phase 2 · registry result, not featured evidence n/a: no completion milestone125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 100%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 97.6%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone NCT02499146 · Phase 1 · registry result, not featured evidence · combination 0%Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0%Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —h NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results— NCT02102490 · Phase 2 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence —Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 18.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 12.9%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 25%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 19.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 20%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 7.2%i NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more results8.9% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3.9%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 2%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 5.2%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02630693 · Phase 2 · registry result, not featured evidence —100mg NCT02630693 · Phase 2 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence — NCT03644186 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence —T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02384239 · Phase 2 · registry result, not featured evidence —100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 16.7%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 0%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 15.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 11.5% NCT02499146 · Phase 1 · registry result, not featured evidence · combination —Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 50%8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 33.3%6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 0%5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 29.3%h NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results25% NCT02102490 · Phase 2 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 33.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 21.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 22.2%Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 27.6%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence 28.6%Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence 41.2%Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 35.9% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 51.6%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 37.5%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 50%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 26.7%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 28.2%i NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more results22.6% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 20.2% NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 29.6%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 18%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 22.7%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 14.1%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 24.6% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 13.5%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 10%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 54.2% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 21.4%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 21.1%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 5.9%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 13.9%100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence 9.5%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 0%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence 30.3%Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 24%Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 16.7%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 26.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20%300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 13.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 33.3%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 11.1%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 12%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 20%25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 40%25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100%125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 83.3%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 87.5%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 15.4% NCT02499146 · Phase 1 · registry result, not featured evidence · combination 40%Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0%Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 25%8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 16.7%6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 33.3%5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | h diarrhoea 87.1% (placebo 27.8%) neutropenia 49.7% (placebo 3.6%) nausea 49.4% (placebo 24.7%) NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more resultsdiarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 200 mg diarrhoea 87.5% nausea 62.5% anaemia 58.3% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 91.7% nausea 58.3% anaemia 41.7% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 95.7% anaemia 47.8% nausea 47.8% NCT03703466 · Phase 2 · registry result, not featured evidence diarrhoea 55.6% fatigue 33.3% nausea 33.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 77.6% fatigue 48.3% nausea 44.8% NCT02308020 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% anaemia 44.4% diarrhoea 44.4% NCT02308020 · Phase 2 · registry result, not featured evidence diarrhoea 53.6% fatigue 39.3% nausea 28.6% NCT02308020 · Phase 2 · registry result, not featured evidence abdominal pain 21.7% diarrhoea 21.7% neutropenia 21.7% NCT02308020 · Phase 2 · registry result, not featured evidence fatigue 52.9% nausea 41.2% diarrhoea 35.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 84.6% fatigue 43.6% nausea 43.6% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% decreased appetite 66.7% vomiting 66.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg anaemia 100% diarrhoea 100% aspartate aminotransferase increased 85.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 85.7% asthenia 71.4% neutropenia 71.4% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 90.9% nausea 66.7% neutrophil count decreased 51.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.5% nausea 67.7% neutrophil count decreased 51.6% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% nausea 75% asthenia 62.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 61.5% nausea 61.5% decreased appetite 42.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.3% asthenia 60% headache 53.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination | i neutropenia 69.4% (placebo 3.6%) arthralgia 42.1% (placebo 40.1%) fatigue 41.2% (placebo 29.3%) NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 49 more resultsneutropenia 67% fatigue 43.8% nausea 36.5% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutrophil count decreased 66.7% (placebo 11.1%) white blood cell count decreased 64.3% (placebo 9.9%) neutropenia 44.6% (placebo 7%) NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 72.4% fatigue 65.1% nausea 37.5% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutropenia 57% anaemia 22% alopecia 17% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutropenia 70% leukopenia 34.6% anaemia 33.8% NCT02600923 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 125mg fatigue 82% nausea 53.9% back pain 46.1% NCT02630693 · Phase 2 · registry result, not featured evidence 100mg fatigue 85.6% nausea 52.2% insomnia 48.9% NCT02630693 · Phase 2 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence diarrhea 65.3% anemia 48.6% platelet count decreased 38.9% NCT03644186 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination nausea 57.1% aspartate aminotransferase increased 50% fatigue 50% NCT03530696 · Phase 2 · registry result, not featured evidence neutrophil count decreased 84.2% platelet count decreased 76.3% white blood cell count decreased 76.3% NCT03530696 · Phase 2 · registry result, not featured evidence · combination 125mg neutrophil count decreased 26.5% hypertension 0% NCT02384239 · Phase 2 · registry result, not featured evidence 100mg neutrophil count decreased 13.9% hypertension 5.6% NCT02384239 · Phase 2 · registry result, not featured evidence 125 mg white blood cell count decreased 83.3% diarrhoea 66.7% neutrophil count decreased 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence 125 mg + 2.5 mg neutrophil count decreased 81% stomatitis 76.2% white blood cell count decreased 71.4% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 100% white blood cell count decreased 100% diarrhoea 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 100 mg neutrophil count decreased 83.3% white blood cell count decreased 66.7% aspartate aminotransferase increased 33.3% NCT01684215 · Phase 2 · registry result, not featured evidence neutropenia 78.8% leukopenia 48.5% fatigue 42.4% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 72% fatigue 40% leukopenia 40% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 91.7% fatigue 83.3% leukopenia 66.7% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 74.7% leukopenia 43.4% fatigue 41% NCT00721409 · Phase 2 · registry result, not featured evidence · combination 300 mg QD nausea 40% fatigue 30% headache 30% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD neutrophil count decreased 100% anaemia 66.7% fatigue 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 150 mg BID abdominal pain 66.7% ggt increased 66.7% nausea 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD nausea 40% headache 26.7% hypertension 26.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100 mg QD white blood cell count decreased 91.7% neutrophil count decreased 58.3% anaemia 41.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100 mg QD abdominal pain upper 33.3% arthralgia 33.3% back pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg BID arthralgia 33.3% fall 33.3% fatigue 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg QD hypophosphataemia 66.7% blood alkaline phosphatase increased 33.3% breast pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg BID alt increased 50% anaemia 50% cough 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD neutrophil count decreased 77.8% white blood cell count decreased 77.8% anaemia 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD fatigue 25% ggt increased 18.8% arthralgia 12.5% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg QD ggt increased 14.7% covid-19 10.7% ast increased 9.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 25 mg BID nausea 60% neutrophil count decreased 60% white blood cell count decreased 60% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 25 mg QD neutrophil count decreased 80% white blood cell count decreased 70% anaemia 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 125mg mucositis oral 100% neutrophil count decreased 100% platelet count decreased 100% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 100% neutrophil count decreased 83.3% fatigue 50% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 96.9% neutrophil count decreased 87.5% fatigue 65.6% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination neutrophil count decreased 61.5% platelet count decreased 57.7% white blood cell count decreased 57.7% NCT02499146 · Phase 1 · registry result, not featured evidence · combination dyspnea 60% neutrophil count decreased 60% skin and subcutaneous tissue disorders - other 60% NCT02913430 · Phase 1 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 8 mg diarrhea 75% oral mucositis 75% dry skin 50% NCT03238196 · Phase 1 · registry result, not featured evidence · combination 6 mg fatigue 83.3% oral mucositis 83.3% dry mouth 66.7% NCT03238196 · Phase 1 · registry result, not featured evidence · combination 5 mg anemia 100% constipation 100% dry skin 100% NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation context differs: registered conditions differ.
- ePopulation context differs: prior_therapy differs (unrestricted versus naive).
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 1 versus Phase 2.
- hPopulation comparability has not been reviewed for 23 of these studies.
- iPopulation comparability has not been reviewed for 53 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Abemaciclib
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 19 further endpoints in the CSV export.
Palbociclib
show 1 more result
show 1 more result
show 3 more results
+ 65 further endpoints in the CSV export.
Breast Cancer
Shared mechanism: CDK4 and CDK6 · full Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02107703 · Phase 3 · active, not recruiting
This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.
Next expected readout: December 2026 · NCT05305924 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)
Result source: NCT02107703
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)
Result source: NCT02297438
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Abemaciclib: 25 of 25 rows · Palbociclib: 25 of 25 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Abemaciclib Rows use multiple source trials | Palbociclib Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants | 72.2% (n=446) vs 56.1% (n=223) placeboa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 42.1% (n=38) vs 15% (n=20) Fulvestrant NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 85.8% (n=444) vs 71.2% (n=222) placeboa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 8 other source trials66.3% (n=347) vs 39.7% (n=174) Fulvestrant NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 79.3% (n=169) vs 80.1% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 77.9% (n=145) vs 79.6% (n=142) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 76.9% (n=169) vs 73.1% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 78.1% (n=128) vs 71.8% (n=131) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 76.5% (n=34) vs 58% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 84% (n=50) vs 58% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 81% (n=84) vs 58% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 42.4% (n=132)c,d,b NCT02102490 · Phase 2 4 other source trials13% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.9% (n=52) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.1% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence 9.1% (n=22) NCT02308020 · Phase 2 · registry result, not featured evidence | 64% (n=47)c,d,b NCT02668666 · Phase 2 · registry result, not featured evidence 1 other source trial83.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| Disease Control responder rate · % of participants No placebo or comparator arm | 67.4% (n=132)e,d,b NCT02102490 · Phase 2 4 other source trials40.7% (n=27) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 51.7% (n=58) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 39.3% (n=28) NCT02308020 · Phase 2 · registry result, not featured evidence 26.1% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence | 85.7% (n=42)125 mg + 2.5 mge,d,b NCT01684215 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months | NA vs 25.6 placebo monthsa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 13.36 vs 13.03 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 20.1 vs 16.7 placebo monthsa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7 other source trials10.4 vs 9 Fulvestrant months NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 22.4 vs 19.4 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 30.3 vs 24.9 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.7 vs 11.2 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 20.9 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.2 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.3 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 8.6 monthsc,d,b NCT02102490 · Phase 2 4 other source trials11.12 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 17.54 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 5.78 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 4.63 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 5.55 months*125mgf,c,d,b NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted show 1 more dose4.14 months*100mg NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted |
| EORTC QLQ-C30 Appetite Loss absolute change · score Appetite Loss | 16.9 vs 1.9 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose16.9 vs 1.9 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | 2.99 vs 1.04 Capecitabine scoreg,e,b Appetite loss NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Constipation absolute change · score Constipation | 16.9 vs 1.9 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose22.4 vs 1.9 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | 3.91 vs -1.45 Capecitabine scoreg,e,b Constipation NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Fatigue absolute change · score Fatigue | 13.9 vs 4 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose13.6 vs 4 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | 3.85 vs 5.79 Capecitabine scoreg,e,b Fatigue NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Insomnia absolute change · score Insomnia | 0.5 vs -1.9 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose-1.1 vs -1.9 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | -3.04 vs -5.94 Capecitabine scoreg,e,b Insomnia NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Pain absolute change · score Pain | 3.5 vs 2.9 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose4.8 vs 2.9 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | -1.79 vs -1.9 Capecitabine scoreg,e,b Pain NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Physical Functioning absolute change · score Physical Functioning | -5.5 vs -0.3 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose-3.2 vs -0.3 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | -1.73 vs -2.94 Capecitabine scoreg,e,b Physical functioning NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Role Functioning absolute change · score Role Functioning | -11.4 vs -2.2 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose-11.3 vs -2.2 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | -1.09 vs -4.97 Capecitabine scoreg,e,b Role functioning NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| EORTC QLQ-C30 Social Functioning absolute change · score Social Functioning | -3.5 vs -0.7 Anastrozole score @ 2wkf,g,e,b NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose-8.3 vs -0.7 Anastrozole score @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | -0.67 vs -3.01 Capecitabine scoreg,e,b Social functioning NCT02028507 · Phase 3 · registry result, not featured evidence · combination |
| Ki67 absolute change · percentage points | -90.52% (n=52) vs -62.78% (n=56) Anastrozole @ 2wkf,c NCT02441946 · Phase 2 · registry result, not featured evidence show 1 more dose-92.86% (n=59) vs -62.78% (n=56) Anastrozole @ 2wk NCT02441946 · Phase 2 · registry result, not featured evidence · combination | 25% (n=107) vs 33% (n=94) Anastrozole + Palbociclib @ 2wkc NCT04436744 · Phase 2 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants | 35.2% (n=446) vs 16.1% (n=223) placeboa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 26.3% (n=38) vs 10% (n=20) Fulvestrant NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 46.4% (n=444) vs 38.3% (n=222) placeboa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 12 other source trials21% (n=347) vs 8.6% (n=174) Fulvestrant NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 37.3% (n=169) vs 31.6% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 43.4% (n=145) vs 38% (n=142) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 40.2% (n=169) vs 33.9% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 52.3% (n=128) vs 43.5% (n=131) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 50% (n=112) vs 49.1% (n=108) Anastrozole + Palbociclib @ 12wk NCT04436744 · Phase 2 · registry result, not featured evidence · combination 44.1% (n=34) vs 33.3% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 55.6% (n=27) vs 39.4% (n=66) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 42% (n=50) vs 33.3% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 55.3% (n=21) vs 39.4% (n=66) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 42.9% (n=84) vs 33.3% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 55.4% (n=65) vs 39.4% (n=66) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 19.7% (n=132)c,d,b NCT02102490 · Phase 2 2 other source trials53.6% (n=224) NCT02441946 · Phase 2 · registry result, not featured evidence · combination 46.4% (n=224) NCT02441946 · Phase 2 · registry result, not featured evidence · combination | 30% (n=47)c,d,b NCT02668666 · Phase 2 · registry result, not featured evidence 2 other source trials47.6% (n=42)125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 60.6% (n=33)*1000 mgf,h,e,b NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted show 3 more doses19.4% (n=31)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 3.8% (n=26)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 6.7% (n=15)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted | 33.3% (n=54)*h,e,b NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted 8 other source trials0% (n=3) @ 24wk*100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 6.7% (n=15) @ 24wk*150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 10% (n=10) @ 24wk*300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 0% (n=16) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=6) @ 24wk*75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 4% (n=75) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted |
| Overall Survival time to event · months | 45.8 vs 37.25 placebo monthsa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1 other source trial26.71 vs 26.02 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 53.9 vs 51.2 placebo monthsf,a,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose53.8 vs 49.8 placebo months NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Overall Survival time to event · months No placebo or comparator arm | 22.32 monthsc,d,b NCT02102490 · Phase 2 4 other source trials10.06 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 13.38 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 7.13 months NCT02308020 · Phase 2 · registry result, not featured evidence 2.93 months NCT02308020 · Phase 2 · registry result, not featured evidence | 35.61 months*c,d,b NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted 6 other source trials20.73 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 21.39 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence NA months NCT03530696 · Phase 2 · registry result, not featured evidence 35.1 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 37.9 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination NA months125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination |
| PFS time to event · months | 16.4 vs 9.3 placebo monthsa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.28 vs 1.95 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 24.8 vs 14.5 placebo monthsa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9 other source trials9.2 vs 3.8 Fulvestrant months NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 21.5 vs 13.9 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 21.6 vs 16.4 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7.3 vs 9.4 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 7.5 vs 9.4 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 8 vs 10.6 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 26.1 vs 10.2 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 18.1 vs 10.2 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.2 vs 10.2 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 6 monthsc,d,b NCT02102490 · Phase 2 8 other source trials2.07 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 4.41 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 1.45 months NCT02308020 · Phase 2 · registry result, not featured evidence 1.22 months NCT02308020 · Phase 2 · registry result, not featured evidence 13.6 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 2.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination NA months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 29.4 months*c,d,b NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted 8 other source trials9.33 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 11.3 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence 9.13 months NCT02668666 · Phase 2 · registry result, not featured evidence 8.3 months NCT03530696 · Phase 2 · registry result, not featured evidence 16.9 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 30.4 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination 6.53 months100mg NCT02384239 · Phase 2 · registry result, not featured evidence 9.4 months125mg NCT02384239 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 25.6%i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 28 more results5.3% NCT02102490 · Phase 2 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 16.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 8.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 25%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 34.5%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 6.6%Abemaciclib NCT02441946 · Phase 2 · registry result, not featured evidence 2.7%Abemaciclib + Anastrozole NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 2 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence 17.5% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestonej NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 48 more resultsn/a: no completion milestone NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestone NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 69.1%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 34%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 19.5% NCT01864746 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02600923 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 1.1%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 0%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 1.4% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence 12.5%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 2.6%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination 2.8% NCT03691493 · Phase 2 · registry result, not featured evidence · combination 3.6% NCT04436744 · Phase 2 · registry result, not featured evidence · combination 0%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%100mg NCT02384239 · Phase 2 · registry result, not featured evidence 22.1%B: Letrozole Then Letrozole + Palb NCT02296801 · Phase 2 · registry result, not featured evidence · combination 27.5%C: Palbociclib Then Letrozole + Pa NCT02296801 · Phase 2 · registry result, not featured evidence · combination 13.4%D: Letrozole + Palbociclib NCT02296801 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 100%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 97.6%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 28 more results— NCT02102490 · Phase 2 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence —Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 1.3%Abemaciclib NCT02441946 · Phase 2 · registry result, not featured evidence 1.4%Abemaciclib + Anastrozole NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 2 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 18.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 12.9%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 25%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 19.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 20%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 7.2%j NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 48 more results8.9% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3.9%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 2%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 5.2%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT01864746 · Phase 3 · registry result, not featured evidence 2.3% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02630693 · Phase 2 · registry result, not featured evidence —100mg NCT02630693 · Phase 2 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence — NCT03644186 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence —T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 0.9% NCT04436744 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02384239 · Phase 2 · registry result, not featured evidence —100mg NCT02384239 · Phase 2 · registry result, not featured evidence —B: Letrozole Then Letrozole + Palb NCT02296801 · Phase 2 · registry result, not featured evidence · combination —C: Palbociclib Then Letrozole + Pa NCT02296801 · Phase 2 · registry result, not featured evidence · combination —D: Letrozole + Palbociclib NCT02296801 · Phase 2 · registry result, not featured evidence · combination 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 16.7%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 0%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 15.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 29.3%i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 28 more results25% NCT02102490 · Phase 2 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 33.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 21.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 22.2%Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 27.6%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence 28.6%Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence 41.2%Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib NCT02441946 · Phase 2 · registry result, not featured evidence —Abemaciclib + Anastrozole NCT02441946 · Phase 2 · registry result, not featured evidence · combination 1.4%Abemaciclib + Anastrozole Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence · combination 7.4%Abemaciclib + Anastrozole Cycle 2 NCT02441946 · Phase 2 · registry result, not featured evidence · combination 1.3%Abemaciclib Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence 35.9% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 51.6%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 37.5%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 50%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 26.7%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 28.2%j NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 48 more results22.6% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 20.2% NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 29.6%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 18%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 22.7%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 14.1%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 10.1% NCT01864746 · Phase 3 · registry result, not featured evidence 24.6% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 13.5%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 10%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 54.2% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 21.4%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 21.1%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 4.5% NCT04436744 · Phase 2 · registry result, not featured evidence · combination 5.9%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 13.9%100mg NCT02384239 · Phase 2 · registry result, not featured evidence —B: Letrozole Then Letrozole + Palb NCT02296801 · Phase 2 · registry result, not featured evidence · combination —C: Palbociclib Then Letrozole + Pa NCT02296801 · Phase 2 · registry result, not featured evidence · combination —D: Letrozole + Palbociclib NCT02296801 · Phase 2 · registry result, not featured evidence · combination 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence 9.5%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 0%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence 30.3%Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 24%Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 16.7%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 26.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20%300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 13.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 33.3%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 11.1%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 12%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 20%25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 40%25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | i diarrhoea 87.1% (placebo 27.8%) neutropenia 49.7% (placebo 3.6%) nausea 49.4% (placebo 24.7%) NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 26 more resultsdiarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 200 mg diarrhoea 87.5% nausea 62.5% anaemia 58.3% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 91.7% nausea 58.3% anaemia 41.7% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 95.7% anaemia 47.8% nausea 47.8% NCT03703466 · Phase 2 · registry result, not featured evidence diarrhoea 55.6% fatigue 33.3% nausea 33.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 77.6% fatigue 48.3% nausea 44.8% NCT02308020 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% anaemia 44.4% diarrhoea 44.4% NCT02308020 · Phase 2 · registry result, not featured evidence diarrhoea 53.6% fatigue 39.3% nausea 28.6% NCT02308020 · Phase 2 · registry result, not featured evidence abdominal pain 21.7% diarrhoea 21.7% neutropenia 21.7% NCT02308020 · Phase 2 · registry result, not featured evidence fatigue 52.9% nausea 41.2% diarrhoea 35.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 41.9% constipation 36.5% fatigue 25.7% NCT02441946 · Phase 2 · registry result, not featured evidence · combination diarrhoea 46.5% nausea 30.9% fatigue 28.6% NCT02441946 · Phase 2 · registry result, not featured evidence · combination diarrhoea 38.7% constipation 34.7% fatigue 22.7% NCT02441946 · Phase 2 · registry result, not featured evidence diarrhoea 84.6% fatigue 43.6% nausea 43.6% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% decreased appetite 66.7% vomiting 66.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg anaemia 100% diarrhoea 100% aspartate aminotransferase increased 85.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 85.7% asthenia 71.4% neutropenia 71.4% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 90.9% nausea 66.7% neutrophil count decreased 51.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.5% nausea 67.7% neutrophil count decreased 51.6% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% nausea 75% asthenia 62.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 61.5% nausea 61.5% decreased appetite 42.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.3% asthenia 60% headache 53.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination | j neutropenia 69.4% (placebo 3.6%) arthralgia 42.1% (placebo 40.1%) fatigue 41.2% (placebo 29.3%) NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 42 more resultsneutropenia 67% fatigue 43.8% nausea 36.5% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutrophil count decreased 66.7% (placebo 11.1%) white blood cell count decreased 64.3% (placebo 9.9%) neutropenia 44.6% (placebo 7%) NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 72.4% fatigue 65.1% nausea 37.5% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutropenia 57% anaemia 22% alopecia 17% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination leukopenia 99.2% (placebo 69.9%) neutropenia 95.7% (placebo 23.4%) anemia 73.9% (placebo 30.3%) NCT01864746 · Phase 3 · registry result, not featured evidence neutropenia 70% leukopenia 34.6% anaemia 33.8% NCT02600923 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 125mg fatigue 82% nausea 53.9% back pain 46.1% NCT02630693 · Phase 2 · registry result, not featured evidence 100mg fatigue 85.6% nausea 52.2% insomnia 48.9% NCT02630693 · Phase 2 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence diarrhea 65.3% anemia 48.6% platelet count decreased 38.9% NCT03644186 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination nausea 57.1% aspartate aminotransferase increased 50% fatigue 50% NCT03530696 · Phase 2 · registry result, not featured evidence neutrophil count decreased 84.2% platelet count decreased 76.3% white blood cell count decreased 76.3% NCT03530696 · Phase 2 · registry result, not featured evidence · combination neutropenia 41.1% neutrophil count decreased 23.2% asthenia 22.3% NCT04436744 · Phase 2 · registry result, not featured evidence · combination 125mg neutrophil count decreased 26.5% hypertension 0% NCT02384239 · Phase 2 · registry result, not featured evidence 100mg neutrophil count decreased 13.9% hypertension 5.6% NCT02384239 · Phase 2 · registry result, not featured evidence 125 mg white blood cell count decreased 83.3% diarrhoea 66.7% neutrophil count decreased 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence 125 mg + 2.5 mg neutrophil count decreased 81% stomatitis 76.2% white blood cell count decreased 71.4% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 100% white blood cell count decreased 100% diarrhoea 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 100 mg neutrophil count decreased 83.3% white blood cell count decreased 66.7% aspartate aminotransferase increased 33.3% NCT01684215 · Phase 2 · registry result, not featured evidence neutropenia 78.8% leukopenia 48.5% fatigue 42.4% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 72% fatigue 40% leukopenia 40% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 91.7% fatigue 83.3% leukopenia 66.7% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 74.7% leukopenia 43.4% fatigue 41% NCT00721409 · Phase 2 · registry result, not featured evidence · combination 300 mg QD nausea 40% fatigue 30% headache 30% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD neutrophil count decreased 100% anaemia 66.7% fatigue 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 150 mg BID abdominal pain 66.7% ggt increased 66.7% nausea 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD nausea 40% headache 26.7% hypertension 26.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100 mg QD white blood cell count decreased 91.7% neutrophil count decreased 58.3% anaemia 41.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100 mg QD abdominal pain upper 33.3% arthralgia 33.3% back pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg BID arthralgia 33.3% fall 33.3% fatigue 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg QD hypophosphataemia 66.7% blood alkaline phosphatase increased 33.3% breast pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg BID alt increased 50% anaemia 50% cough 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD neutrophil count decreased 77.8% white blood cell count decreased 77.8% anaemia 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD fatigue 25% ggt increased 18.8% arthralgia 12.5% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg QD ggt increased 14.7% covid-19 10.7% ast increased 9.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 25 mg BID nausea 60% neutrophil count decreased 60% white blood cell count decreased 60% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 25 mg QD neutrophil count decreased 80% white blood cell count decreased 70% anaemia 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation context differs: prior_therapy differs (unrestricted versus naive).
- bThe assessment timepoint is not available for both results.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation context differs: registered conditions differ.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 2 versus Phase 3.
- hTrial phases differ: Phase 1 versus Phase 2.
- iPopulation comparability has not been reviewed for 28 of these studies.
- jPopulation comparability has not been reviewed for 46 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Abemaciclib
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 25 further endpoints in the CSV export.
Palbociclib
show 1 more result
show 1 more result
show 3 more results
+ 61 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Palbociclib's landscape